0.95Open0.95Pre Close0 Volume62 Open Interest2.00Strike Price0.00Turnover191.14%IV-15.26%PremiumAug 16, 2024Expiry Date1.09Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9133Delta0.3864Gamma0.83Leverage Ratio-0.0013Theta-0.0007Rho-0.76Eff Leverage0.0004Vega
Karyopharm Therapeutics Stock Discussion
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months fo...
No comment yet